Atrial Fibrillation
Tuesday, April 23rd, 2013
Am Coll Cardiology: April 23, 2013 Objectives The purpose of this study was to investigate long-term outcomes of freedom from atrial fibrillation (AF) after pulmonary vein (PV) isolation using cryoballoon ablation with balloon-size selection based on individual PV diameters. Background Data are lacking on long-term outcomes from cryoablation and on the most effective balloon size. Methods This was […]
Atrial Fibrillation
Tuesday, April 23rd, 2013
Neurology: April 17, 2013 Background: Based on the higher frequency of paroxysmal atrial fibrillation during night and early morning hours, we sought to analyze the association between newly diagnosed atrial fibrillation and wake-up ischemic cerebrovascular events. Methods: We prospectively assessed every acute ischemic stroke and TIA patient admitted to our hospital between 2008 and 2011. We used a […]
Atrial Fibrillation
Tuesday, April 23rd, 2013
CIRCEP: April 11, 2013 Background—Left atrial (LA) ganglionated plexi (GP) are part of the intrinsic cardiac autonomic nervous system and implicated in the pathogenesis of atrial fibrillation (AF). High frequency stimulation (HFS) is used to identify GP sites in humans. The effect of ablation on neural pathways connecting GPs in humans is unknown. Methods and Results—30 […]
Atrial Fibrillation
Tuesday, April 23rd, 2013
CIRCEP: April 11, 2013 Background—Pulmonary vein isolation (PVI) has increasingly been used to cure atrial fibrillation, but concerns have recently been raised that subclinical brain damage may occur due to microembolization during these procedures. We compared the occurrence of bubble formation seen on intracardiac echocardiography (ICE) and the microembolic signals (MESs) detected by transcranial Doppler on […]
Atrial Fibrillation
Tuesday, April 23rd, 2013
Circulation: Arrhythmia and Electrophysiology: February 26, 2013 Background—Ablation of high-frequency sources in patients with atrial fibrillation (AF) is an effective therapy to restore sinus rhythm. However, this strategy may be ineffective in patients without a significant dominant frequency (DF) gradient. The aim of this study was to investigate whether sites with high-frequency activity in human AF […]
Clinical Trials
Tuesday, April 23rd, 2013
AHA Stroke: April 18, 2013 The global burden of stroke on patients, their relatives, health systems, and the economies that support them is tremendous. In an unprecedented move, the World Health Organization (WHO) and the United Nations have responded to this challenge by declaring the fight against stroke a top pri- ority in their drive to […]
Clinical Trials
Tuesday, April 23rd, 2013
STROKEAHA: April 18, 2013 Background and Purpose—We aimed to evaluate safety and tolerability of a novel operator-independent ultrasound device among stroke-free volunteers. Methods—A headframe containing 18 ultrasound transducers (each operating at 2 MHz, pulsed-wave) was used to expose both temporal windows and the suboccipital window. Read more
Clinical Trials
Tuesday, April 23rd, 2013
Eur Heart J: April 16, 2013 Aims Digoxin is recommended for long-term rate control in paroxysmal, persistent, and permanent atrial fibrillation (AF). While some analyses suggest an association of digoxin with a higher mortality in AF, the intrinsic nature of this association has not been examined in propensity-matched cohorts, which is the objective of the current […]
Clinical Trials
Tuesday, April 23rd, 2013
BMC Cardiovascular Disorders: April 15, 2013 Background Few data on the thromboembolic (TE) risk of paroxysmal and persistent atrial fibrillation (AF) are available. This study aimed to assess the incidence of TE events in paroxysmal and persistent AF. Methods We performed a subset post hoc analysis of 771 patients with paroxysmal and 463 with persistent […]
Therapies
Tuesday, April 23rd, 2013
STROKEAHA: April 18, 2013 Background and Purpose—Acute intraprocedural thrombus formation complicating endovascular cerebral aneurysm treatment is often treated with intra-arterial or intravenous administration of thrombolytic agents or glycoprotein IIb/IIIa (GpIIb/IIIa) inhibitors. We sought to evaluate the morbidity and mortality associated with such treatments using a large multihospital database. Methods—Using the Premier Perspective Database, we examined outcomes […]
